Five things for pharma marketers to know: Thursday, April 28, 2016

Five things for pharma marketers to know: Thursday, April 28, 2016

Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug

Senate committee condemns Valeant's business model

Senate committee condemns Valeant's business model

The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare Communications Group has hired Kipp Jarecke-Cheng as global chief communications officer.

Five things for pharma marketers to know: Wednesday, April 27, 2016

Five things for pharma marketers to know: Wednesday, April 27, 2016

Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula

Following positive outcomes data, a new diabetes class is on the rise

Following positive outcomes data, a new diabetes class is on the rise

Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.

Five things for pharma marketers to know: Tuesday, April 26, 2016

Five things for pharma marketers to know: Tuesday, April 26, 2016

FDA panel says Duchenne drug is not effective; Bill Ackman to appear before Senate committee investigating pricing issues; Daiichi Sankyo to open new headquarters

About.com launches first standalone health site Verywell

About.com launches first standalone health site Verywell

Verywell.com presents physician-reviewed health and wellness content that aims to be "gentler" than other health websites.

Biogen under investigation for patient-assistance programs

Biogen under investigation for patient-assistance programs

The drugmaker disclosed in its first-quarter earnings report that it is being investigated over ties to nonprofit foundations.

FCB agency veteran, Renée Wills, joins Kinch

FCB agency veteran, Renée Wills, joins Kinch

After six years as president of Trio, Renée Wills has joined newly formed agency Kinch.

Five things for pharma marketers to know: Monday, April 25, 2016

Five things for pharma marketers to know: Monday, April 25, 2016

Valeant names new CEO; Novartis weighs sales of stake in Roche; FDA ad panel to recommend DMD drug

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.

Five things for pharma marketers to know: Friday, April 22, 2016

Five things for pharma marketers to know: Friday, April 22, 2016

AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying

Biogen turned to DTC to address 'low awareness' of MS drug

Biogen turned to DTC to address 'low awareness' of MS drug

Biogen CEO George Scangos told investors that the company's DTC campaign for Tecfidera was designed to address low awareness for the drug.

Five things for pharma marketers to know: Thursday, April 21, 2016

Five things for pharma marketers to know: Thursday, April 21, 2016

Allergan plans sales blitz for Kybella; Novartis U.S. lead steps down; analysts say PCSK9 sales are disappointing so far

An explainer: some of IBM Watson Health's key partnerships

An explainer: some of IBM Watson Health's key partnerships

IBM Watson Health has publicly announced deals with 18 different companies and patient organizations over the past few years.

Brazilian agencies create billboard that kills Zika-carrying mosquitoes

Brazilian agencies create billboard that kills Zika-carrying mosquitoes

The billboards themselves operate on simple principles: fool mosquitoes into thinking they've found a human, and then trap them until they die of dehydration.

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

Watson Health partners with drug and devicemakers to tap into real-world data

Watson Health partners with drug and devicemakers to tap into real-world data

Industry is partnering with Watson to try and solve some of healthcare's most pressing questions.

Competition drives down sales of J&J's Olysio

Competition drives down sales of J&J's Olysio

The company said growth in its immunology portfolio offset declining Olysio sales.

Five things for pharma marketers to know: Tuesday, April 19, 2016

Five things for pharma marketers to know: Tuesday, April 19, 2016

Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class

Is virtual reality the ultimate emotive storytelling tool?

Is virtual reality the ultimate emotive storytelling tool?

Wieden+Kennedy Portland's VR work for the National Multiple Sclerosis Society lets wheelchair-bound patients experience their favorite activities again, like dancing or surfing.

How Watson for Oncology is advancing cancer care

How Watson for Oncology is advancing cancer care

IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.

Bayer creates new role: VP of comms for consumer health

Bayer creates new role: VP of comms for consumer health

He plans to expand the company's consumer health marketing.

Five things for pharma marketers to know: Monday, April 18, 2016

Five things for pharma marketers to know: Monday, April 18, 2016

Valeant mulls over fire sale; research shows that Opdivo helps advanced melanoma patients survive longer; AstraZeneca considers Medivation

Challenges exist, even as excitement grows for big data market

Challenges exist, even as excitement grows for big data market

The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.

What is cognitive computing, and what does it look like in healthcare?

What is cognitive computing, and what does it look like in healthcare?

Already, there's cognitive cooking for your kitchen and cognitive coaching for your daily run. What's Watson's vision for medicine?

A look at Watson Health in New York

A look at Watson Health in New York

The editorial staff of MM&M recently visited IBM Watson's offices in New York. What ensued was the creation of Watson Week.

Five things for pharma marketers to know: Friday, April 15, 2016

Five things for pharma marketers to know: Friday, April 15, 2016

Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs

MM&M's Agency questionnaire is now available

MM&M's Agency questionnaire is now available

The questionnaire gives agencies the opportunity to contribute information to MM&M's definitive Agency A-to-Z directory, which will be published in the July issue.

Five things for pharma marketers to know: Thursday, April 14, 2016

Five things for pharma marketers to know: Thursday, April 14, 2016

Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license

Second-generation IBM star pushes for partnerships

Second-generation IBM star pushes for partnerships

With a lead role in IBM Watson's bold gambit to transform healthcare, Kathy McGroddy-Goetz ranks as one of the enterprise's most important individuals.

U.S. drug spend jumped 12% in 2015

U.S. drug spend jumped 12% in 2015

2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.

Five things for pharma marketers to know: Wednesday, April 13, 2016

Five things for pharma marketers to know: Wednesday, April 13, 2016

Sanofi is reportedly interested in buying Medivation; Sean Parker funds $250 million cancer research institute; FDA will review Merck's allergy biologic

Creative partners should push pharma clients to tell better stories

Creative partners should push pharma clients to tell better stories

Industry criticism can create opportunities for drugmakers and other healthcare organizations to create a stronger narrative.

FDA committee votes no on Clovis lung-cancer drug

FDA committee votes no on Clovis lung-cancer drug

The FDA advisory committee voted 12-1 against approving the therapy, citing safety issues and requesting more data.

Five things for pharma marketers to know: Tuesday, April 12, 2016

Five things for pharma marketers to know: Tuesday, April 12, 2016

California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use

The FDA approves AbbVie's and Roche's blood cancer drug

The FDA approves AbbVie's and Roche's blood cancer drug

Analysts have estimated the drug could reach $2 billion in sales in the next four years.

Five things for pharma marketers to know: Monday, April 11, 2016

Five things for pharma marketers to know: Monday, April 11, 2016

Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review

Five things for pharma marketers to know: Friday, April 8, 2016

Five things for pharma marketers to know: Friday, April 8, 2016

Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease

Five things for pharma marketers to know: Thursday, April 7, 2016

Five things for pharma marketers to know: Thursday, April 7, 2016

Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's

Omnicom merges Corbett, LLNS into TBWA/ WorldHealth brand

Omnicom merges Corbett, LLNS into TBWA/ WorldHealth brand

LLNS CEO Sharon Callahan has been named CEO of TBWA/WorldHealth, which is based in New York.

InVentiv Health files for IPO

InVentiv Health files for IPO

It operates a number of ad agencies, like GSW and Palio, as well as a group of PR firms that includes Chandler Chicco Agency.

Drugmakers go to DTC to promote IBS drugs

Drugmakers go to DTC to promote IBS drugs

The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.

MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Five things for pharma marketers to know: Wednesday, April 6, 2016

Five things for pharma marketers to know: Wednesday, April 6, 2016

Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire

New mobile app seeks to address medication adherence

New mobile app seeks to address medication adherence

CeyHello, a newly launched social networking mobile app, tackles medication adherence by connecting patients, caregivers and family members.

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Tuesday, April 5, 2016

Five things for pharma marketers to know: Tuesday, April 5, 2016

Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza

Eli Lilly's failed trial could spell the end for CETP inhibitors

Eli Lilly's failed trial could spell the end for CETP inhibitors

The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.

Five things for pharma marketers to know: Monday, April 4, 2016

Five things for pharma marketers to know: Monday, April 4, 2016

Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data

The FDA issues warning letter to Shionogi over co-pay voucher

The FDA issues warning letter to Shionogi over co-pay voucher

The drugmaker marketed a co-pay assistance voucher that failed to provide any risk information about its drug Ulesfia.

Five things for pharma marketers to know: Friday, April 1, 2016

Five things for pharma marketers to know: Friday, April 1, 2016

GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance

Five things for pharma marketers to know: Thursday, March 31, 2016

Five things for pharma marketers to know: Thursday, March 31, 2016

The FTC asks for more info about Pfizer-Allergan deal; the FDA loosens guidelines for abortion-inducing drug; startup to deliver Truvada through an app

Another physician group raises concerns about DTC

Another physician group raises concerns about DTC

The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.

Five things for pharma marketers to know: Wednesday, March 30, 2016

Five things for pharma marketers to know: Wednesday, March 30, 2016

There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center

LehmanMillet becomes Precisioneffect following acquisition

LehmanMillet becomes Precisioneffect following acquisition

The Boston-based agency was acquired by Precision Medicine Group in May.

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.

W2O, Lagrant Foundation team up on healthcare diversity push

W2O, Lagrant Foundation team up on healthcare diversity push

The healthcare-focused agency network is committed to spending $50,000 over three years to the Future Leaders in Healthcare Fellowship Program.

WPP acquires CMI, retains minority stake in Compas

WPP acquires CMI, retains minority stake in Compas

WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.

Ascension Health rolls out first ad campaign for VA

Ascension Health rolls out first ad campaign for VA

The Catholic health system worked with FleishmanHillard and GSD&M to create the integrated campaign touting its partnership with the Department of Veterans Affairs.

Five things for pharma marketers to know: Tuesday, March 29, 2016

Five things for pharma marketers to know: Tuesday, March 29, 2016

Lawmakers call out high price of Xtandi; Novo Nordisk breaks ground in North Carolina; Sanofi poaches top research scientist from AstraZeneca

Devicemakers eye market for drug adherence

Devicemakers eye market for drug adherence

Insulet's skin-adhesive technology is being used to improve adherence for patients taking biologics.

Five things for pharma marketers to know: Monday, March 28, 2016

Five things for pharma marketers to know: Monday, March 28, 2016

Experts say DTC spending is a waste; Alder BioPharma's migraine drug meets study goal; sources tell Stat that execs are leaving Verily Life Sciences

Teva targets opioid abuse with the absurd

Teva targets opioid abuse with the absurd

The drugmaker launched a three-part video series that uses humor to address prescription drug abuse.

Giant hires new Philadelphia GM and creative director

Giant hires new Philadelphia GM and creative director

Giant appointed Ben Mallory, who has held creative leadership roles at AstraZeneca, as its new executive creative director.

Sudler & Hennessey acquires West Coast digital marketing firm

Sudler & Hennessey acquires West Coast digital marketing firm

Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.

Five things for pharma marketers to know: Friday, March 25, 2016

Five things for pharma marketers to know: Friday, March 25, 2016

Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren't prescribed blood thinners; the FDA issues generic opioid guidance

Five things for pharma marketers to know: Thursday, March 24, 2016

Five things for pharma marketers to know: Thursday, March 24, 2016

Valeant hiked price of assisted-suicide drug; Bristol-Myers Squibb acquires autoimmune drugmaker; the FDA approves Teva's asthma drug

Facebook's Everson: Agencies lagging on mobile creative

Facebook's Everson: Agencies lagging on mobile creative

Facebook has found that 43% of people who watch the first three seconds of a video will stay for 10 seconds. To create engagement, agencies need to rethink the creative approach.

Politics led to DTC uproar, but curbs unlikely in current climate

Politics led to DTC uproar, but curbs unlikely in current climate

Anti-DTC measures are unlikely to be enacted even though the backlash itself is a function of political change.

Precision for Medicine acquires ACT Oncology

Precision for Medicine acquires ACT Oncology

The scientific services company expands its portfolio to include expertise in oncology clinical studies.

Five things for pharma marketers to know: Wednesday, March 23, 2016

Five things for pharma marketers to know: Wednesday, March 23, 2016

Propeller Health partners with Boehringer Ingelheim; judge votes in favor of Merck in HCV patent dispute; the FDA approves Eli Lilly's Taltz

The truth about a doctor's day: know-it-all patients and no time for lunch

The truth about a doctor's day: know-it-all patients and no time for lunch

There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.

Five things for pharma marketers to know: Tuesday, March 22, 2016

Five things for pharma marketers to know: Tuesday, March 22, 2016

Apple debuts CareKit; Anthem sues Express Scripts; Sanofi reportedly moving out of Paris

Sermo opens up platform to healthcare marketers

Sermo opens up platform to healthcare marketers

The Facebook for doctors launches Pages, allowing healthcare companies to establish a presence on Sermo and engage with physicians.

Five things for pharma marketers to know: Monday, March 21, 2016

Five things for pharma marketers to know: Monday, March 21, 2016

Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development

AstraZeneca hires new head of corporate affairs

AstraZeneca hires new head of corporate affairs

AstraZeneca appointed Jennie Younger, who has held senior communications roles at GlaxoSmithKline, Deutsche Bank, and FTI Consulting, as its vice president of global corporate affairs.

Five things for pharma marketers to know: Friday, March 18, 2016

Five things for pharma marketers to know: Friday, March 18, 2016

OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader

Five things for pharma marketers to know: Thursday, March 17, 2016

Five things for pharma marketers to know: Thursday, March 17, 2016

Entresto's sales are still lower than expected; GSK CEO Witty to retire in 2017; tech assistants sometimes fail to account for women's health needs

Calling all health-tech startups: MM&M launches 2016 Shark Tank

Calling all health-tech startups: MM&M launches 2016 Shark Tank

The deadline has been extended to April 8.

Amgen wins PCSK9 patent case against Sanofi and Regeneron

Amgen wins PCSK9 patent case against Sanofi and Regeneron

A jury ruled in favor of Amgen, saying its patents for Repatha are valid.

Five things for pharma marketers to know: Wednesday, March 16, 2016

Five things for pharma marketers to know: Wednesday, March 16, 2016

CDC issues new opioid prescribing guidelines; Sanofi partnership will focus on oral-drug development; MannKind hires Amgen exec

Xifaxan misses sales mark amidst Valeant leadership changes

Xifaxan misses sales mark amidst Valeant leadership changes

IBS drug Xifaxan missed the company's sales projection for the fourth quarter of 2015 by $180 million.

Easy navigation beats out trustworthiness for health info, survey finds

Easy navigation beats out trustworthiness for health info, survey finds

Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.

Five things for pharma marketers to know: Tuesday, March 15, 2016

Five things for pharma marketers to know: Tuesday, March 15, 2016

The FDA will prioritize certain generic drug applications; Valeant posts fourth-quarter loss; medical marijuana drug shines in Phase-III trial

Astellas reshapes commercial leadership team

Astellas reshapes commercial leadership team

The drugmaker promoted three to keep pace with the evolving healthcare landscape.

Five things for pharma marketers to know: Monday, March 14, 2016

Five things for pharma marketers to know: Monday, March 14, 2016

BMS says docs are prescribing Opdivo more than Keytruda; Valeant reportedly weighed replacing CEO during sick leave; the FDA expands use of Xalkori

Palio consolidates, closes two offices

Palio consolidates, closes two offices

The agency plans to collaborate more with the rest of its network, inVentiv Health.

Five things for pharma marketers to know: Friday, March 11, 2016

Five things for pharma marketers to know: Friday, March 11, 2016

Valeant CEO reportedly tells staffers that the worst is behind them; Sanofi hires chief medical officer from Novartis; PhRMA CEO says pricing debate is misinformed

Five things for pharma marketers to know: Thursday, March 10, 2016

Five things for pharma marketers to know: Thursday, March 10, 2016

The VA will cover Gilead HCV drugs for veterans; Valeant settles specialty pharmacy lawsuit; Gleevec's price has dramatically increased since approval

The FDA wants to study DTC tactics

The FDA wants to study DTC tactics

The agency has proposed two studies to investigate the use of superimposed text and the use of animated characters.

Sudler & Hennessey creates science and learning focus

Sudler & Hennessey creates science and learning focus

Sudler & Hennessey is reorganizing the ways its businesses report to its dual CEOs.

Don't forget to enter the MM&M Awards

Don't forget to enter the MM&M Awards

For 2016 MM&M enhanced the program with the addition of several new categories.

Five things for pharma marketers to know: Wednesday, March 9, 2016

Five things for pharma marketers to know: Wednesday, March 9, 2016

Amarin settles with the FDA over off-label promotion suit; mobile apps often share medical information with third parties; drug spending rose 12% in 2014

Five things for pharma marketers to know: Tuesday, March 8, 2016

Five things for pharma marketers to know: Tuesday, March 8, 2016

Gilead Sciences has spent about $100 million on Harvoni ads; Allergan taps Khloé Kardashian for Kybella campaign; Sanofi and Merck end vaccines venture

Providers, devicemakers lag in IT defense

Providers, devicemakers lag in IT defense

While it's made great strides, the healthcare industry is still behind in some technology and information safeguards.

MM&M launches Hall of Femme awards program

MM&M launches Hall of Femme awards program

The Hall of Femme will honor the most-senior female leaders in the pharmaceutical, medical device and agency sectors of the healthcare industry.

Drugmakers eye growing IBS market with DTC push

Drugmakers eye growing IBS market with DTC push

Three drugmakers are making big pushes for their second-line treatments as they eye a massive market with few new prescription drug options.

Five things for pharma marketers to know: Monday, March 7, 2016

Five things for pharma marketers to know: Monday, March 7, 2016

European regulators launch speedier drug approval process: AbbVie and Boehringer Ingelheim to partner on psoriasis drug; the FDA approves hemophilia B drug

Senators propose an end to pharma ad tax deduction

Senators propose an end to pharma ad tax deduction

The proposed legislation would forbid drugmakers from writing off advertising as a tax deduction.

OPINION


Click here to learn about the Agency Issue. 

Email Newsletters